AbbVie Inc. (NYSE:ABBV) management will conduct a conference call for 30th October 2020 at 9:00 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.abbvie.com
Earnings Expectation
AbbVie Inc. manufacturer of pharma products, is reporting third quarter earnings results on Friday 30th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 2.76 per share from $ 12722.30 million in revenue. For the full year, analysts predict revenues of $ 45480.30 million, while looking forward to income of $ 10.42 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 50,000.00 million ~ $ 50,000.00 million, where as bottomline are predicted in a range of $ 10.35 ~ $ 10.45 per share
Click Here For More Historical Outlooks Of AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçets diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenströms macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
